Table 1 Activity of ceftazidime-avibactam and comparator agents against levofloxacin-resistant E. coli; ATLAS, 2012–2018
Antimicrobial | MIC50 (mg/L) | MIC90 (mg/L) | Range (mg/L) | %S | %I | %R |
|---|---|---|---|---|---|---|
ESBL-positive (N = 5749) | ||||||
Ceftazidime-avibactam | 0.12 | 0.5 | ≤ 0.015– ≥ 256 | 99.0 | – | 1.0 |
Ceftazidimea | 32 | 128 | 0.12– ≥ 256 | 5.3 | 14.8 | 79.9 |
Cefepimea | 32 | 32 | ≤ 0.12– ≥ 64 | 3.0 | 10.0 | 86.9 |
Ampicillin | ≥ 64 | ≥ 64 | 1– ≥ 64 | 0.2 | – | 99.8 |
Amoxicillin-clavulanatea | 16 | 32 | ≤ 0.12– ≥ 64 | 29.3 | – | 70.7 |
Piperacillin-tazobactam | 8 | 64 | ≤ 0.25– ≥ 256 | 64.8 | 15.2 | 20.0 |
Aztreonama | 32 | 128 | 0.06– ≥ 256 | 0.2 | 8.2 | 91.6 |
Imipenem | 0.25 | 0.25 | ≤ 0.03– ≥ 16 | 98.5 | 0.4 | 1.1 |
Meropenem | 0.03 | 0.06 | ≤ 0.004– ≥ 32 | 98.5 | 0.6 | 1.0 |
Colistinb (N = 4470) | 0.25 | 1 | ≤ 0.06– ≥ 16 | 99.1 | – | 0.9 |
Amikacin | 4 | 16 | 0.5– ≥ 128 | 83.4 | – | 16.6 |
Tigecycline | 0.25 | 0.5 | ≤ 0.015– ≥ 16 | 95.7 | – | 4.3 |
ESBL-negative (N = 5091) | ||||||
Ceftazidime-avibactam | 0.12 | 0.25 | ≤ 0.015– ≥ 256 | 99.6 | – | 0.4 |
Ceftazidime | 0.25 | 4 | ≤ 0.015– ≥ 256 | 88.5 | 2.3 | 9.2 |
Cefepime | ≤ 0.12 | 1 | ≤ 0.12– ≥ 64 | 91.8 | 3.8 | 4.4 |
Ampicillin | ≥ 64 | ≥ 64 | ≤ 0.5– ≥ 64 | 17.4 | – | 82.6 |
Amoxicillin-clavulanate | 8 | 32 | ≤ 0.12– ≥ 64 | 51.4 | – | 48.6 |
Piperacillin-tazobactam | 2 | 64 | ≤ 0.12– ≥ 256 | 81.9 | 5.0 | 13.1 |
Aztreonam | 0.12 | 4 | ≤ 0.015– ≥ 256 | 88.9 | 2.7 | 8.3 |
Imipenem | 0.12 | 0.25 | ≤ 0.03– ≥ 16 | 99.1 | 0.3 | 0.6 |
Meropenem | 0.03 | 0.06 | ≤ 0.004– ≥ 32 | 99.3 | 0.3 | 0.4 |
Colistinb (N = 3864) | 0.25 | 1 | ≤ 0.06– ≥ 16 | 99.0 | – | 1.0 |
Amikacin | 2 | 8 | ≤ 0.25– ≥ 128 | 95.1 | – | 4.9 |
Tigecycline | 0.25 | 0.5 | ≤ 0.015–4 | 94.6 | – | 5.4 |